Associate ProfessorCatherine Blizzard

Principal Research Fellow - Neurodegenerative Disease Research

Menzies Institute for Medical Research

  • Principal Research Fellow - Neurodegenerative Disease Research
    Menzies Institute for Medical Research

FUNDED PROJECTS

  • GRANT
    Acquisition of a high-frequency ultrasound platform to supercharge discovery research in Tasmania
    1 Jan 2027 - 31 Dec 2029
    People funded by this grant:
    • Premilovac D,
    • Sutherland B,
    • Young K,
    • Flies A,
    • Guven N
    Project Total: $141,000; This equipment grant application to the Ian Potter Foundation will lead to acquisition of a new, purpose built and state of the art ultrasound machine for preclinical work. Currently available machines at UTAS are clinical machines and are not able to adequately support preclinical imaging due to temporal and spatial resolution limits. This new machine will enable live in vivo imaging of any organ in the rat/mouse/zebra fish, measurement of cardiovascular function, targeted drug delivery using microbubbles (contrast agents) and an ultrasound guided micro-injection platform for delivery of compounds or genetic material without off target effects. Funded by: Ian Potter Foundation - Grant - Medical Research ($141,000); University of Tasmania ($141,000).
  • CONSULTANCY/CONTRACT RESEARCH
    Cure MND Government grant
    1 Jan 2027 - 31 Dec 2029
    People funded by this grant:
    • Blizzard C
    Project Total: $310,000; Grant co-funded by FightMND, Tasmanian State Government (via MND Tas) and Menzies to support the development of neuronal excitability assays for pre clinical research into MND. Funded by: FightMND ($110,000); MND Tasmania ($200,000); University of Tasmania ($50,000).
  • GRANT
    Harnessing genomics to find treatments for anorexia nervosa
    1 Jan 2027 - 30 Jun 2028
    People funded by this grant:
    • Reay W,
    • Blizzard C,
    • Foldi C,
    • Fortune A
    Project Total: $95,000; Anorexia nervosa is a serious mental health condition that causes people to restrict the amount of food they eat, with symptoms of distressing anxiety about their weight and appearance. Unfortunately, anorexia nervosa has one of the highest mortality rates of any mental health condition, due to complications of malnutrition, and costs Australia billions of dollars a year. Despite this immense impact, there are still no approved drugs that can help people living with anorexia. This project seeks to use information from our genes to pinpoint which drugs may be useful as treatments for anorexia. We will then take promising drugs and investigate how they impact nerve cells grown in a dish. By combining these different approaches, we will be able shortlist drugs that may be promising new treatments which can then be candidates for clinical trial. Funded by: Donation via Menzies Institute for Medical Research - Donation ($95,000); University of Tasmania.
  • GRANT
    The Neurotoxicity Landscape: Mapping Environmental Risk Factors for Parkinson's and MND Prevalence in Australia
    1 Jul 2026 - 30 Jul 2027
    People funded by this grant:
    • de Graaff B,
    • Alty J,
    • Callisaya M,
    • Blizzard C,
    • Breslin M
    Project Total: $110,017; Approximately 90% of Parkinsons and Motor Neurone Disease (MND) cases are due to a combination of environmental and genetic factors. Environmental risk factors that have been linked to increased risk include agricultural pesticides, heavy metals (e.g. manganese) and air traffic-related pollution. Many of these toxins have been shown to induce neurodegeneration through multiple mechanisms. In response, numerous countries have banned these chemicals, however Australia has been slow to follow. For example, paraquat has been banned in 78 countries, yet the Australian regulator has been reviewing a proposed ban for more than 27 years. The aims of this project will be to generate epidemiological data to identify associations between exposure to a broad range of environmental risk factors and Parkinsons and MND. Firstly, we will geographically map Parkinsons and MND cases across Australia. We will then map environmental risk factor variables including land use (e.g. types of agriculture, mining) and air pollution, along with sociodemographic variables (alcohol and tobacco use, chronic health conditions, psychological distress, overweight and obesity). Regression models will assess associations between risk factors and prevalence of Parkinsons and MND. Importantly, we will build an online interactive map to allow users to visualise clusters of Parkinsons, MND, or both, to identify if these are associated with each of the exposures. We will use the National Health Data Hub, a longitudinal dataset that contains health data for almost all Australians (excl WA and the NT). This will be the first research of its kind globally, to bring together multiple neurodegenerative conditions and to identify associations between prevalence of these and a broad range of environmental risk factors. The findings will be critical for informing public health policy, particularly concerning the regulation of persistent environmental toxins. Funded by: Perpetual Trustees - IMPACT Philanthropy Application Program ($110,017); University of Tasmania.
  • GRANT
    Investigating the therapeutic utility of targeting B-vitamin pathways in ALS
    1 Feb 2026 - 1 Feb 2027
    People funded by this grant:
    • Reay W,
    • Blizzard C
    Project Total: $99,689; B vitamins play a key role in maintaining brain health throughout the lifespan, including in critical processes such as neurotransmitter synthesis, cellular metabolism (e.g., homocysteine), and myelination. Multiple lines of evidence suggest that deficiencies and impaired functionality of B-vitamins are linked to neurodegeneration. Interestingly, recent work led by the CIA has further demonstrated that dysregulation of B-vitamins may be linked to the pathogenesis of ALS. These findings are timely and exciting as very recently an ultra-high dose formulation of methylcobalamin (active form of vitamin B12) was approved in Japan to slow functional decline in people living with ALS [JETALS trial (NCT03548311)]. Whilst this may be an important advance in the clinical management of ALS, and initial case-reports outside of Japan are promising, more evidence is needed to understand the underlying mechanisms. Further investigating the cellular mechanisms of the interplay between ALS risk and B-vitamin signalling may not only reveal insights into disease pathogenesis but further provide opportunities to identify synergistic treatment combinations that could amplify therapeutic benefits. Funded by: MND Australia - Innovator ($99,688); University of Tasmania.
  • GRANT
    Motor Nerone Disease in Australia: generating epidemiological and health economic evidence
    1 Jan 2026 - 31 Dec 2026
    People funded by this grant:
    • Nguyen LTA,
    • de Graaff B,
    • Blizzard C
    Project Total: $20,000; This project aims to generate the first comprehensive national estimates of motor neurone disease (MND) incidence, prevalence, survival, and economic burden in Australia using linked administrative health datasets from the National Health Data Hub, including: hospital admissions, emergency department presentations, MBS, PBS, Aged Care, National Disability Insurance Scheme, and Death Funded by: Donation via Menzies Institute for Medical Research - Donation ($20,000); University of Tasmania.
  • GRANT
    Unravelling the impact of sex chromosomes on healthy brain aging
    1 Jan 2026 - 31 Dec 2029
    People funded by this grant:
    • Taberlay P,
    • Blizzard C,
    • Woodhouse A
    Project Total: $1,761,443; Older women possess a larger cognitive reserve than older men, but cognitive impairment associated with aging progresses at a faster rate in females. We posit that understanding the complex interactions between sex chromosomes, hormones and epigenomes will provide a molecular explanation for these differences and provide critical insight into the fundamentals of brain function. Our project will apply state of the art technologies to reveal how sex chromosomes and hormones impact DNA packaging, reading and translation; cell function and ultimately, behaviour and cognitive ability. This new knowledge is vital for facilitating a trajectory of healthy aging for all Australians, especially First Nations mobs. Funded by: Australian Research Council - Grant-Discovery Indigenous ($1,761,440); University of Tasmania ($143,804).
  • GRANT
    Acquiring a 5-colour confocal microscope for research to improve health outcomes in Tasmania
    1 Nov 2024 - 31 Oct 2025
    People funded by this grant:
    • Young K,
    • Fletcher J,
    • King A,
    • Sutherland B,
    • Blizzard C
    Project Total: $150,000; We aim to purchase a spinning disc confocal microscope to be housed in the medical sciences precinct at the University of Tasmania. The microscope will be used for current and future medical research projects, and will be available for use by other STEM researchers, increasing our imaging capacity and capability. Funded by: Ian Potter Foundation - Grant ($150,000); University of Tasmania ($226,997).
  • GRANT
    Can we tailor excitation therapy for MND?
    1 Feb 2024 - 1 Feb 2028
    People funded by this grant:
    • Blizzard C
    Project Total: $680,000; Dr Cathy Blizzard will investigate the cell mechanisms behind why too much talking is not a good thing in motor neuron disease and test exciting new ways to selectively protect nerve cells from this over communication and the detrimental cascades it initiates, where the nerve cells need it the most. Funded by: FightMND - Fellowship-Bill Guest Mid-Career Fellowship ($680,000); University of Tasmania.
  • GRANT
    Oligodendrocytes and TDP-43 pathology in ALS
    1 Feb 2024 - 1 Feb 2027
    People funded by this grant:
    • Walker A,
    • Barton S,
    • Cullen C,
    • Scotter E,
    • San Gil
    Project Total: $1,000,000; The guiding hypothesis of this proposal is that oligodendrocytes are key drivers of, and protectors against, neurodegeneration in ALS. Our preliminary evidence clearly demonstrates that neuronal TDP- 43 pathology causes distinct OL alterations in ALS mouse models, which correlate with previous evidence of OL alterations in human disease. We have devised an innovative program of research employing advanced technologies based on the most recent advances in ALS research to study established and new mouse models, human iPSC 3D organoid systems, and human post-mortem tissues. Our crossdisciplinary team of emerging leaders in ALS research will build upon our converging preliminary work to delineate a new framework of how neurodegeneration progresses in ALS. These studies will define the mechanisms of oligodendrocytic contribution to ALS pathogenesis. Funded by: FightMND - Grant-Discovery; University of Queensland; University of Tasmania.
  • GRANT
    Australian Preclinical Research ALS (APRALS) Network: a roadmap for effective translation of therapeutics for sporadic MND
    3 Jul 2023 - 3 Jul 2027
    People funded by this grant:
    • Turner B,
    • Akkari A,
    • Blair I,
    • Blizzard C,
    • Luikinga S
    Project Total: $1,000,000; This project will launch Australian Preclinical Research ALS (APRALS), a national collaborative network which aims to accelerate development of novel treatment candidates towards clinical trials in MND. The network will bring together distinct and advanced expertise in human stem cell technology and animal models of MND to develop a novel class of powerful DNA designer drugs targeting key pathologies in sporadic MND. We predict that targeting signature pathologies in sporadic MND will significantly improve outcomes in human and animal models of MND, providing a rich pipeline of promising treatment candidates for clinical trials applicable to the majority of people living with MND. Funded by: Motor Neurone Disease Research Australia - Grant-Daniel McLoone Major Research Initiative; University of Melbourne; Murdoch University; Macquarie University; Flinders University; University of Queensland; University of Tasmania.
  • GRANT
    Do upper and lower motor neurons need different treatments to stop neurodegeneration in ALS?
    1 Mar 2023 - 31 Dec 2025
    People funded by this grant:
    • Blizzard C
    Project Total: $15,000; This PhD project aims to interrogate the differential vulnerability of upper and lower neurons to disease mechanisms of ALS and will inform our approach to treating patients suffering from ALS. Funded by: Motor Neurone Disease Research Australia - Scholarship-PhD Top-Up Grant ($15,000); University of Tasmania.
  • GRANT
    A Collaborative Multivariable Approach to Prevent the Spread of Corticomotor Dysfunction in ALS
    1 Jan 2023 - 31 Mar 2026
    People funded by this grant:
    • Blizzard C,
    • Walker A,
    • Balbi M,
    • Woodhouse A,
    • Premilovac D
    Project Total: $500,000; The most frequent presentation of a patient with ALS is increased motor cortex hyperexcitability and cytoplasmic build-up of TDP-43. It remains unclear how these pathophysiology lead to the widespread destruction of the corticomotor system. Our preliminary data indicates that TDP-43 in the cytoplasm may be causing neuronal hyperexcitability. We propose to discover (1) the cell signalling pathways that TDP-43 triggers hyperexcitability, (2) how upper motor neuron hyperexcitability spreads through the network (3) if different regions require altered excitability to be selectively and differentially modulated. This project may establish a novel and targeted drug delivery approach for patients with ALS. Funded by: Motor Neurone Disease Research Australia - Grant-Daniel McLoone MND Research Prize ($500,000); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Tasmanian Masonic Medical Research Foundation: Neurodegenerative disease research
    1 Jan 2023 - 31 Dec 2026
    People funded by this grant:
    • Dickson T,
    • Blizzard C
    Project Total: $235,000; Funding support for HDR student project costs for students working in the Dickson and Blizzard labs on Neurodegenerative diseases. Funded by: Masonic Medical Research Foundation Limited ($235,000); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Turning Cells into Circuits: Putting the pieces together to solve the puzzle of MND
    1 Jan 2023 - 31 Dec 2027
    People funded by this grant:
    • Blizzard C,
    • Dickson T
    Project Total: $115,688; New therapeutic targets are required for ALS. To interrogate the role of individual cell types and thus reveal these targets, we need to selectively affect subpopulations of cells that exist within larger heterogeneous cell networks with complex connections. Critical subpopulations include cells from discrete anatomical regions (brain and spinal cord) and specific types of cells (cortical and spinal MNs, Interneurons and glia) all with specific and defined connections. Independently manipulating these subpopulations in a traditional primary culture preparation, or even within an organoid model, is impossible. We will overcome this limitation by developing, validating and using a customised microfluidic primary cell culture platform. Funded by: FightMND ($260,688); University of Tasmania.
  • GRANT
    Myelin: wrapping up neural network function and behaviour
    1 Jan 2022 - 31 Dec 2025
    People funded by this grant:
    • Cullen C,
    • Makowiecki K,
    • Favre-Bulle I
    Project Total: $802,257; Identifying the biological causes of mental health disorders is critical for the development of effective treatment or prevention strategies. Neurons communicate via electrical signalling and the precise timing of this signalling is vital for appropriate information processing. Recent work by our team has shown that myelinating oligodendrocytes adapt to dynamically regulate action potential conduction speed, indicating that changes in myelin could have robust impacts on information processing in the brain. Altered myelin content in the brain has been linked to numerous neurodevelopmental and neuropsychiatric disorders including autism, attention deficit hyperactivity disorder, schizophrenia, major depressive disorder, and post-traumatic stress disorder. These disorders also exhibit characteristic changes in functional network connectivity and information processing in the brain, suggesting that aberrant myelination may be a key underlying feature of maladaptive information processing and neurobehavioural symptom expression in these disorders. Our team will use innovative transgenic mouse and zebrafish models to determine how developmental myelination and myelin plasticity regulate information processing in the brain and contribute to the development of phenotypic behaviours associated with mental illness. Understanding the role of myelin in regulating brain function and behaviour will provide mechanistic insight into the aetiology of idiopathic mental health symptoms and could identify a new therapeutic target for their treatment. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Ideas; University of Queensland; University of Tasmania.
  • GRANT
    The Many Paths to Inhibitory Dysfunction and Excitotoxicity in ALS: Glial cells, not just innocent bystanders?
    1 Jan 2022 - 31 Dec 2022
    People funded by this grant:
    • Dickson T,
    • Clark R,
    • Young K,
    • Blizzard C
    Project Total: $98,339; Amyotrophic lateral sclerosis (ALS) is a devastating and universally fatal late onset motor neuron disease for which there are currently no effective treatments or cure. Development of effective therapeutics for ALS is complicated by the fact that it shows substantial clinical heterogeneity, with a high degree of variability in susceptibility, site of onset of symptoms, age of onset, and severity and progression of disease. However, what underpins this heterogeneity is not understood. Here we will utilise a unique cohort of human tissue, alongside highly characterised transgenic model tissue, to investigate the role of individual glial populations in triggering inhibitory pathogenesis. The findings of this project will contribute important knowledge to the problem of clinical heterogeneity in ALS, and prove invaluable for the development of therapeutic candidates that can be targeted to the motor system during the symptomatic phase. Funded by: Motor Neurone Disease Research Australia - Grant - Innovator ($98,339); University of Tasmania.
  • GRANT
    Toward tailored excitation therapy for amyotrophic lateral sclerosis
    1 Jan 2022 - 31 Dec 2026
    People funded by this grant:
    • Blizzard C,
    • Dickson T
    Project Total: $624,821; Amyotrophic lateral sclerosis (ALS) is an unrelenting and fatal disease in which motor neurons of the motor cortex and spinal cord rapidly degenerate. One of the earliest detectable clinical markers of ALS is hyperexcitability. We have discovered that upper motor neurons in the motor cortex and lower motor neurons in the spinal cord, may be differentially vulnerable to pathogenic effects of hyperexcitability, and possibly the resulting excitotoxicity. Furthermore we have evidence to suggest that age and sex, two important patient demographic variables in ALS also may influence the vulnerability of motor neurons to excitotoxicity. This indicates that a blanket treatment approach toward excitotoxicity in ALS may not be appropriate for the protection of all motor neurons. An innovative and potentially more effective strategy is to specifically tailor treatment to the differential changes that are occurring in the brain and spinal cord through disease progression. With leading-edge experimental design in appropriate models this project will determine how age and sex impacts excitotoxicity in mouse models of ALS (Aim 1), if upper and lower motor neurons are differentially vulnerable to disease using mouse models and patient derived induced pluripotent stem cells (Aim 2) and whether diffuse sub-threshold transcranial magnetic stimulation, a non-invasive form of central nervous system network stimulation, can regionally treat upper and lower motor neurons to halt disease progression in mouse models of ALS (Aim 3). This project brings together a team of CIs and AIs that have a demonstrated excellence in all aspects necessary for this project. The CI team (Catherine Blizzard and Tracey Dickson) have a long and productive collaborative track record; 29 publications and $3.5 million in funding together. This is the first time a disease treatment has been trialled in ALS that applies approaches tailored to address pathology in distinct regions of the corticomotor system. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Ideas ($1,249,642); University of Tasmania.
  • GRANT
    Can we stop the spread of TDP-43 pathology in ALS?
    1 Jan 2020 - 31 Dec 2022
    People funded by this grant:
    • Blizzard C,
    • Reale L
    Project Total: $15,000; ALS is caused by a destruction of the neurons that are part of the motor system in the brain and spinal cord. It is not known how the disease moves through this system and we have few effective treatments to stop the spread. In Laura's PHD she aims to discover why one population of neurons can make another population stop working, ie. How the disease spreads, and test a non invasive intervention to stop this destruction from spreading. If we can better understand why the whole system fails and how to protection against this then we can develop new effective treatments for ALS. Funded by: Motor Neurone Disease Research Australia - Scholarship-PhD Top-Up Grant ($15,000); University of Tasmania.
  • GRANT
    HDAC6 inhibition to rescue axon degeneration in ALS
    30 Sep 2019 - 31 Dec 2023
    People funded by this grant:
    • King A,
    • Cook T,
    • Guven N,
    • Van Den Bosch L,
    • Dickson T
    Project Total: $997,046; We will test an HDAC6 inhibitor in models of ALS. We will investigate the HDA6 inhibitor activity of novel compounds Funded by: FightMND - Grant - Drug Development Grant ($997,046); University of Tasmania.
  • GRANT
    Neuronal excitability in ALS a focus on TDP43 mislocalisation
    1 Mar 2019 - 31 Dec 2021
    People funded by this grant:
    • Blizzard C
    Project Total: $11,250; In the vast majority of ALS cases, pathological movement of a protein called TDP-43 from the cell nucleus into the outer parts of the cell occurs. The pathological mechanism of how mislocalised TDP-43 causes motor neuron death is not known.. My PhD project hypothesizes that the presence of TDP-43 in the cytoplasm affects the activity of neurons, which eventually causes their death. I will be identifying if alterations in activity are one of the earliest changes as a consequence of TDP-43 misprocessing and if we can potentially prevent this pathogenic mechanism from driving the onset and progression of ALS. Funded by: Motor Neurone Disease Research Australia - Scholarship-PhD Top-Up Grant ($11,250); University of Tasmania.
  • GRANT
    Can estrogen protect against synaptic disturbances in ALS?
    1 Feb 2019 - 31 Dec 2019
    People funded by this grant:
    • Blizzard C,
    • Dickson T
    Project Total: $99,700; Deficits in neuroplasticity may be one of the earliest events in Frontotemporal Dementia (FTD). Our studies have identified that TDP-43, a frequently aggregated protein in FTD specifically affects neuroplasticity at the dendrite spine in mouse models of FTD. Furthermore we have identified that this pathogenic mechanism is likely due to the translocation of TDP-43 into the cytoplasm. It is now time to unravel the role of mislocalised TDP-43 in neuroplasticity deficits that may drive FTD and perform vital pilot investigations to determine if we can modulate these circuitry deficits non-invasively using transcranial magnetic stimulation (TMS). We will address the hypothesis: 'Neuroplasticity deficits are an early disease causing event in FTD that can be modulated with TMS' using novel mouse models and multiphoton live imaging. This project will be lead by Dr Catherine Blizzard in conjunction with Dr Kaylene Young, who will strategically use the Dementia Australia funding to unravel the earliest changes in neuroplasticity that may drive FTD and generate the pilot data necessary to provide evidence for a large-scale pre clinical trial investigating novel ways to ameliorate neuroplasticity deficits that characterises FTD Funded by: Motor Neurone Disease Research Australia - Grant - Innovator ($99,700); University of Tasmania.
  • GRANT
    Do therapeutically targetable deficits in neuroplasticity drive Frontotemporal Dementia?
    1 Jan 2019 - 1 May 2022
    People funded by this grant:
    • Blizzard C,
    • Young K,
    • Lewis K,
    • Dickson T
    Project Total: $75,000; Deficits in neuroplasticity may be one of the earliest events in Frontotemporal Dementia (FTD). Our studies have identified that TDP-43, a frequently aggregated protein in FTD specifically affects neuroplasticity at the dendrite spine in mouse models of FTD. Furthermore we have identified that this pathogenic mechanism is likely due to the translocation of TDP-43 into the cytoplasm. It is now time to unravel the role of mislocalised TDP-43 in neuroplasticity deficits that may drive FTD and perform vital pilot investigations to determine if we can modulate these circuitry deficits non-invasively using transcranial magnetic stimulation (TMS). We will address the hypothesis: 'Neuroplasticity deficits are an early disease causing event in FTD that can be modulated with TMS' using novel mouse models and multiphoton live imaging. This project will be lead by Dr Catherine Blizzard in conjunction with Dr Kaylene Young, who will strategically use the Dementia Australia funding to unravel the earliest changes in neuroplasticity that may drive FTD and generate the pilot data necessary to provide evidence for a large-scale pre clinical trial investigating novel ways to ameliorate neuroplasticity deficits that characterises FTD. Funded by: Dementia Australia Research Foundation Ltd - Grant-Project Grants ($75,000); University of Tasmania.
  • GRANT
    The pathological effects of Alzheimer's disease on axons
    1 Mar 2018 - 4 Jun 2022
    People funded by this grant:
    • Young K,
    • Blizzard C,
    • Cullen C,
    • Sutherland B
    Project Total: $90,000; Proposed PhD project investigating the role of amyoloid upon axonal dystrophies in the progression of Alzheimer's disease Funded by: Dementia Australia Research Foundation Ltd - Grant-Scholarship ($90,000); University of Tasmania.
  • GRANT
    Preclinical Development of Neuropeptide Y for the Treatment of Motor Neuron Disease
    16 Jun 2017 - 30 Apr 2021
    People funded by this grant:
    • Dickson T,
    • Blizzard C,
    • Pebay A,
    • Walker A,
    • Blizzard L
    Project Total: $936,572; Motor Neuron Disease (MND) is a rapidly progressing neurodegenerative disease. There are no cures and no effective treatments for MND, with people diagnosed having a median survival of only three years from symptom onset. Not knowing the cause of MND or how it progresses through the CNS have been immense barriers to the development of effective therapeutics. We have reached a critical time in MND research. Our research team has been dedicated to researching the mechanism of MND for the last ten years. We are now poised to transition my teams research efforts from determining the cause of this disease to using this knowledge to develop treatments. A critical pathway that our work and others have shown is key to MND is altered network excitability and subsequent excitotoxicity in the cortex. We have recent published and preliminary data that identifies that a critical potential point of intervention in this pathway is via the subclass of inhibitory cells that express neuropeptide Y (NPY). The overarching Aim for this Cure for MND Translational Research Grant is to now target this pathway to develop a treatment. By performing this world-first preclinical trial we will reveal further aspects of disease pathogenesis. Positive outcomes from these trials will identify a candidate compounds for progression to a human trial for the treatment of MND. Funded by: FightMND - Grant-Translational Research Grant ($936,572); University of Tasmania ($50,000).